Clinical Trial: A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder

U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07252908) titled 'A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder' on Nov. 19.

Brief Summary: To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL

Condition: Pulmonary Disease, Chronic Obstructive

Intervention: DRUG: TQC3721 inhalation powder

TQC3721 inhalation powder is target inhibitor.

DRUG: Placebo for TQC3721 inhalation powder

Placebo for TQC3721 inhalation powder.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co....